Farooq Sheikh

Featured in: Favicon

jamanetwork.com Favicon

neurology.org Favicon

bdnews24.com Favicon

insurancethoughtleadership.com Favicon

the-rheumatologist.org Favicon

coverager.com Favicon

ffnews.com Favicon

onlinejcf.com Favicon

n.neurology.org

Articles

Vutrisiran improves cardiac amyloidosis endpoints regardless of disease severity

3 weeks ago | healio.com | Erin T. Welsh |Richard Smith |Farooq Sheikh

• Vutrisiran improved all-cause mortality and recurrent CV independent of disease severity in cardiac amyloidosis. • Regardless of cutoffs, vutrisiran also improved various health and quality of life endpoints. CHICAGO — Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for a broad spectrum of patients with transthyretin amyloidosis with cardiomyopathy, subgroup analyses show.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →